NYSE:EW - Edwards Lifesciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$149.20 +2.52 (+1.72 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$146.68
Today's Range$146.33 - $149.58
52-Week Range$100.20 - $155.22
Volume1.37 million shs
Average Volume1.33 million shs
Market Capitalization$31.22 billion
P/E Ratio39.34
Dividend YieldN/A
Beta0.64
Edwards Lifesciences logoEdwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:EW
CUSIP28176E10
Phone949-250-2500

Debt

Debt-to-Equity Ratio0.14
Current Ratio2.07
Quick Ratio1.63

Price-To-Earnings

Trailing P/E Ratio39.34
Forward P/E Ratio32.22
P/E Growth2.17

Sales & Book Value

Annual Sales$3.44 billion
Price / Sales9.15
Cash Flow$4.2911 per share
Price / Cash34.77
Book Value$13.97 per share
Price / Book10.68

Profitability

EPS (Most Recent Fiscal Year)$3.80
Net Income$583.60 million
Net Margins17.36%
Return on Equity28.60%
Return on Assets15.89%

Miscellaneous

Employees12,200
Outstanding Shares210,780,000
Market Cap$31,222.70

The Truth About Cryptocurrencies

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

How will Edwards Lifesciences' stock buyback program work?

Edwards Lifesciences declared that its board has authorized a share repurchase program on Thursday, December 7th 2017, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its stock is undervalued.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) issued its earnings results on Tuesday, April, 24th. The medical research company reported $1.22 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.11 by $0.11. The medical research company had revenue of $938 million for the quarter, compared to the consensus estimate of $936.69 million. Edwards Lifesciences had a return on equity of 28.60% and a net margin of 17.36%. Edwards Lifesciences's revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company posted $0.94 EPS. View Edwards Lifesciences' Earnings History.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Edwards Lifesciences.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $4.50-$4.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.53. The company issued revenue guidance of $3.5-$3.9 billion, compared to the consensus revenue estimate of $3.85 billion.Edwards Lifesciences also updated its Q2 guidance to $1.05-$1.15 EPS.

What price target have analysts set for EW?

19 Wall Street analysts have issued 12 month target prices for Edwards Lifesciences' stock. Their forecasts range from $115.00 to $180.00. On average, they expect Edwards Lifesciences' stock price to reach $151.8750 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Ratings for Edwards Lifesciences.

What is the consensus analysts' recommendation for Edwards Lifesciences?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Edwards Lifesciences' key competitors?

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the folowing people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 65)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 51)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 56)
  • Mr. Larry L. Wood, Corp. VP of Transcatheter Heart Valve (Age 52)
  • Ms. Catherine M. Szyman, Corp. VP of Critical Care (Age 51)

Has Edwards Lifesciences been receiving favorable news coverage?

News stories about EW stock have been trending positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Edwards Lifesciences earned a news impact score of 0.32 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 46.79 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.08%), Scout Investments Inc. (0.07%), Calamos Advisors LLC (0.05%), Welch & Forbes LLC (0.05%), Cim LLC (0.04%) and Handelsbanken Fonder AB (0.04%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Bank of Montreal Can, Scout Investments Inc., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Welch & Forbes LLC, Winslow Evans & Crocker Inc., Essex Investment Management Co. LLC and Gateway Investment Advisers LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was acquired by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Calamos Advisors LLC, State of Alaska Department of Revenue, Fox Run Management L.L.C., IFM Investors Pty Ltd, DnB Asset Management AS, Xact Kapitalforvaltning AB and First Citizens Bank & Trust Co.. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo and Kieran Gallahue. View Insider Buying and Selling for Edwards Lifesciences.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $149.20.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $31.22 billion and generates $3.44 billion in revenue each year. The medical research company earns $583.60 million in net income (profit) each year or $3.80 on an earnings per share basis. Edwards Lifesciences employs 12,200 workers across the globe.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]


MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  905 (Vote Outperform)
Underperform Votes:  657 (Vote Underperform)
Total Votes:  1,562
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.